Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review

Jedlowski, Patrick; Te, Charisse; Segal, Robert J.; Fazel, Maryam

doi:10.1007/s40257-018-0400-7

Cited by 21 publications

(21 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within the past two decades, there has been an increased incidence of BP and an increased prevalence of diabetes mellitus (DM) among patients with BP. These findings aligns with the timing of approval and marketing of a new class of antihyperglycemic drugs, dipeptidyl-peptidase 4 (DPP-4) inhibitors [8][9][10]. The first DPP-4 inhibitor, sitagliptin, was approved in 2006 by the US Food and Drug Administration (FDA) and thereafter saxagliptin, linagliptin, and alogliptin were approved in 2009, 2011, and 2013, respectively.…”

Section: Introductionmentioning

confidence: 56%

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

Jedlowski

Fazel

2021

Am J Clin Dermatol

Self Cite

View full text Add to dashboard Cite

Background In recent years, an association between dipeptidyl peptidase-4 (DPP-4) inhibitors and bullous pemphigoid has been detected in pharmacovigilance studies in European and Asian countries; however, no pharmacovigilance data have been published yet in the USA. Objective The objective of this study was to examine the relationship between bullous pemphigoid and DPP-4 inhibitors and other oral diabetes mellitus medications in the FDA Adverse Event Reporting System (FAERS). Methods Case/non-case analyses were performed in the FAERS using data from 2006 to 2020 to examine the reporting odds ratio (ROR) signal for bullous pemphigoid for all classes of oral diabetes medications. These analyses were performed under multiple conditions to control for bias: (1) comparison to all other drugs in the FAERS; (2) comparison to other diabetes medications; and (3) comparison to all other diabetes medications where only a single agent was implicated. Results A statistically significant ROR for bullous pemphigoid was found for DPP-4 inhibitors under all conditions: (1) 109.79 (95% confidence interval [CI] 101.61-118.62); (2) 74.46 (95% CI 60.58-91.52); and (3) . A larger signal was seen for non-US Food and Drug Administration (FDA)-approved (anagliptin, vildagliptin, teneligliptin) vs FDA-approved DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin), likely because of an overestimation of the ROR for non-FDA-approved drugs. The largest signal was seen under conditions 1 and 2 with vildagliptin (1) 1022.83 (95%

show abstract

Section: Introductionmentioning

confidence: 56%

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

Jedlowski

Fazel

2021

Am J Clin Dermatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Allergic contact dermatitis and lipodystrophy (including lipohypertrophy) are among the most commonly reported cutaneous complications of both insulin pump and CGM use (Table 1). 4‐9 Also reports of atypical mycobacterial infections were found 10 . We highlight this case of a PG‐like neutrophilic and granulomatous response to increase awareness of a previously uncharacterized cutaneous adverse reaction at sites of insulin pump use.…”

Section: Case Narrativementioning

confidence: 80%

A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes

Pérez

Husain

Magro

et al. 2020

Pediatric Dermatology

View full text Add to dashboard Cite

Continuous subcutaneous insulin infusion (CSII), or insulin pumps, with or without continuous glucose monitoring (CGM) devices have become the standard of care for patients with type 1 diabetes. While increasingly popular, a wide range of reported skin reactions to CSII and CGM devices was found. We present this case of a pyogenic granuloma-like neutrophilic and granulomatous response to an insulin pump to increase awareness of a previously uncharacterized cutaneous adverse reaction at insulin pump infusion sites.

show abstract

“…Some of this improvement could be explained by: titration of pump settings when initiating Omnipod, overcoming challenges that may be experienced with a tubed pump (e.g. insufficient insulin delivery due to air bubbles, kinking, or clogging of tubes [10]), fewer prolonged disconnections from the pump as it can be worn during swimming, showering, and exercise [39], or reduced lipohypertrophy stemming from more infusion site possibilities than with their prior tubed CSII device, enabled by the automatic cannula insertion [23,40,41]. It is also plausible that the multiple basal insulin rate settings, bolus calculator, and features such as extended bolus and temporary basal rate available with Omnipod allow for more responsive insulin delivery than simpler CSII models, which may only offer fixed basal and bolus amounts [10].…”

Section: Discussionmentioning

confidence: 99%

Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system

Carlson

Huyett

Jantz

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review

Cited by 21 publications

References 165 publications

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes

Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system

Contact Info

Product

Resources

About